CENTENE Q2 FY25 earnings call CNC

Centene reported a significant $2.4 billion pretax headwind for FY25 in its Marketplace segment, stemming from a change in risk adjustment transfer assumptions. This was driven by a higher-than-expected percentage of healthy members leaving the market, new sign-ups having higher morbidity, and a step-up in utilization combined with aggressive provider coding. The company is actively repricing its 2026 portfolio in 17 states already, with plans for up to 12 more, aiming to reprice 100% of the book to account for these morbidity shifts and return to profitability.

The Medicaid portfolio produced an unanticipated and unacceptable Health Benefits Ratio (HBR) of 94.9% in Q2. This underperformance was primarily due to an acceleration of medical cost trends in behavioral health (especially ABA), home health (HCBS for complex populations), and high-cost drugs (cancer drugs, gene therapies). The pressure was concentrated in a few states, with Florida alone accounting for 40 basis points of HBR pressure due to inadequate rates for the Children's Medical Services contract.

Centene is actively pulling levers to correct the Medicaid HBR trajectory. 88% of the Medicaid franchise rerates between 7/1/25 and 1/1/26. The company has secured a 2025 composite rate adjustment of 5% compared to 2024, which is stronger than the previous expectation of 4% plus. They are advocating for faster rate correction, policy improvements (e.g., pharmacy management returning to Medicaid plans in one state by Q4), and executing clinical interventions, payment integrity, and network optimization.

The Medicare segment showed favorability, with PDP membership at 7.8 million, roughly flat sequentially, and exceeding expectations. This improved the full-year outlook for PDP. Medicare Advantage is also making progress towards its goal of breakeven in 2027, running slightly favorable to expectations. While STARS performance continues to improve, challenging cut points may make the 85% target difficult to hit, though the 2027 breakeven path does not rely on further STARS improvement.

The full-year adjusted diluted EPS guidance was revised down from $7.25 to $1.75. This change is attributed to a $2.4 billion pretax headwind from Marketplace morbidity shifts, an additional $200 million pretax pressure from Marketplace utilization, and a $2.1 billion pretax headwind from Medicaid HBR changes. These negatives are partially offset by $700 million in pretax favorability from the Medicare segment and $500 million in pretax earnings from SG&A management and growth leverage.

Centene expects to deliver margin improvement across all three core lines of business in 2026. The Marketplace business is being repriced for meaningful margin improvement, leveraging insights from 2025 morbidity data. Medicaid HBR is expected to move in the right direction over the next 12-18 months due to rerating cycles and policy changes. Medicare Advantage will continue its solid progress towards 2027 breakeven. The company plans to pressure-test markets for sustainable growth, harvest synergies, and ensure a resilient platform.

Management views the 'One Big Beautiful Bill Act' (OB3) as having established a new and stable policy floor for its programs. Medicaid provisions offer implementation runway, allowing for strong state partnerships. Marketplace repricing already accounts for program integrity impacts and expected market contraction in 2026. Medicare is tracking potential new CMS policy changes. This clarity allows for firm future planning and reinforces confidence in the staying power of Medicaid, Medicare, and the individual marketplace.